LY83583

LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease[1][2][3][4].

Product Specifications

CAS Number

[91300-60-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Guanylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ly83583.html

Concentration

10mM

Purity

99.84

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C1C=C(NC2=CC=CC=C2)C(C3=C1N=CC=C3)=O

Molecular Formula

C15H10N2O2

Molecular Weight

250.26

Precautions

H315, H319, H335

References & Citations

[1]Lodygin D, et al. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002 Dec;110 (11) :1717-27. |[2]Kontos HA, et al. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke. 1993 Mar;24 (3) :427-34.|[3]Prasad RK, et al. LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Eur J Pharmacol. 1999 Jan 29;366 (1) :101-9.|[4]Ribeiro AC, et al. The effects of intracerebroventricular application of 8-Br-cGMP and LY-83,583, a guanylyl cyclase inhibitor, on sleep-wake activity in rats. Brain Res. 2005 Jul 5;1049 (1) :25-33.